Skip to main content
CHEMCLIN DIAGNOSTICS CO., LTD. logo

CHEMCLIN DIAGNOSTICS CO., LTD. — Investor Relations & Filings

Ticker · 688468 ISIN · CNE100005311 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 511 across all filing types
Latest filing 2022-02-25 Earnings Release
Country CN China
Listing Shanghai Stock Exchange 688468

About CHEMCLIN DIAGNOSTICS CO., LTD.

https://www.chemclin.com/

CHEMCLIN DIAGNOSTICS CO., LTD. specializes in the research, development, and manufacturing of in vitro diagnostic systems and reagents. The company is primarily recognized for its proprietary Light-initiated Chemiluminescent Assay (LiCA) technology, a homogeneous chemiluminescence platform that eliminates the need for washing steps, thereby enhancing testing efficiency and precision. Its product portfolio includes fully automated immunoassay analyzers and a comprehensive range of diagnostic kits covering infectious diseases, cardiac markers, thyroid function, tumor markers, and reproductive health. By integrating advanced biotechnology with automated instrumentation, the company provides clinical laboratories and medical institutions with high-sensitivity diagnostic solutions designed to improve patient care and laboratory workflow.

Recent filings

Filing Released Lang Actions
科美诊断技术股份有限公司2021年度业绩快报公告
Earnings Release Classification · 95% confidence The document is a financial announcement containing preliminary unaudited financial data for the fiscal year 2021, including revenue, profit, assets, and equity figures. It explicitly states that the data are preliminary and unaudited, and the final audited data will be in the company's 2021 Annual Report. The document is short (1650 characters) and serves as a financial results preview or earnings update rather than a full annual report. It does not contain full financial statements or detailed analysis but provides key financial highlights and a risk warning. This matches the characteristics of an Earnings Release (ER), which is an initial announcement of quarterly or periodical financial results with key highlights only. FY 2021
2022-02-25 Chinese
科美诊断技术股份有限公司2021年限制性股票激励计划首次授予激励对象名单（截止首次授予日）
Share Issue/Capital Change Classification · 95% confidence The document is a list of recipients for a restricted stock incentive plan for the year 2021, detailing allocations of restricted stock to directors, senior management, and other employees. It includes specific numbers of shares granted and percentages relative to total shares. The document is short (876 characters) and focuses on stock incentive allocations rather than financial results or management changes. It does not contain financial statements or earnings data, nor is it an announcement of a meeting or voting results. The content fits best under a category related to capital changes or share-based compensation. Given the options, the closest match is 'Share Issue/Capital Change (SHA)' as it relates to share allocations under an incentive plan. Confidence is high due to clear focus on share grants and capital structure impact.
2022-01-25 Chinese
科美诊断技术股份有限公司监事会关于2021年限制性股票激励计划首次授予激励对象名单的核查意见（截止首次授予日）
Regulatory Filings Classification · 95% confidence The document is a supervisory board opinion on the verification of the initial grant list of a 2021 restricted stock incentive plan. It references compliance with company law, securities law, stock exchange listing rules, and internal company regulations. The content focuses on the approval and verification of the incentive plan's initial grant recipients and the grant details. It does not contain financial statements, earnings data, or detailed financial analysis. It is not an announcement of a report publication but a formal verification and approval document related to a stock incentive plan. This type of document fits best under Regulatory Filings (RNS) as it is a compliance and regulatory disclosure related to corporate governance and stock incentive plans, but not a full governance report or remuneration report. The document length is short (1027 characters), and it is not a report publication announcement or a certification letter. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2022-01-25 Chinese
上海荣正投资咨询股份有限公司关于科美诊断技术股份有限公司2021年限制性股票激励计划首次授予事项之独立财务顾问报告
Capital/Financing Update Classification · 95% confidence The document is an Independent Financial Advisor Report related to a 2021 restricted stock incentive plan for the company 科美诊断技术股份有限公司. It details the approval procedures, grant conditions, grant details, and the impact on financials. It is not a general annual or quarterly report, nor an earnings release or a regulatory announcement. It is a standalone advisory report on a specific capital incentive plan, which aligns with the category of Capital/Financing Update (CAP). The document length is sufficient and contains detailed substantive content, not just an announcement or certification. Therefore, the best fitting classification is CAP.
2022-01-25 Chinese
科美诊断技术股份有限公司关于向激励对象首次授予限制性股票的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the first grant of restricted stock under the company's 2021 restricted stock incentive plan. It includes specifics such as grant date, number of shares, grant price, eligibility, approval procedures, legal and financial advisor opinions, and accounting treatment. The content focuses on the stock incentive plan implementation and related disclosures rather than financial results or management discussion. It is not an annual or interim report, earnings release, or a general regulatory filing. It is a capital-related update specifically about stock-based compensation and equity incentives. Therefore, the document fits best under the category of Capital/Financing Update (CAP). The document length and detail confirm it is the actual announcement, not a brief notice or report publication announcement.
2022-01-25 Chinese
科美诊断技术股份有限公司第一届监事会第十四次会议决议公告
Share Issue/Capital Change Classification · 95% confidence The document is a formal announcement from the supervisory board of a company regarding the approval of a restricted stock grant under an equity incentive plan. It includes details about the meeting, the approval of the stock grant, and references to compliance with relevant laws and regulations. The document is short (1130 characters) and is an announcement of a corporate action related to share issuance to employees, specifically the initial grant of restricted shares. It does not contain financial statements or detailed financial data, nor is it a full report or presentation. It is not a report publication announcement since it contains substantive content about the approval. The content fits best under 'Share Issue/Capital Change' (SHA) as it announces the issuance of restricted shares under an incentive plan.
2022-01-25 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.